Officer buying at ProMetic Life Sciences (T:PLI)

Jonathan Booth, a Senior Officer, acquired 75,000 Common Shares on a direct ownership basis at a price of US$1.207 on October 6th, 2017. This represents a $113,600 investment into the company's shares and an account share holdings change of greater than 100%.

ProMetic Life Sciences is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.